

2. Food and Drug Administration. Use of ozone-depleting substances: removal of essential-use designations. Final rule. Fed Regist 2005;70:17167-92.

3. United Nations Environment Programme. Production and consumption of ozone depleting substances under the Montreal Protocol

1986–2004. November 2005 (<https://wedocs.unep.org/handle/20.500.11822/8109>).

4. United States Patent and Trademark Office. Drug pricing initiatives. 2021 (<https://www.uspto.gov/initiatives/drug-pricing-initiatives>).

5. Rabin AS, Harlan EA, Ambinder AJ.

Small devices, big problems: addressing the global warming potential of metered-dose inhalers. *Ann Am Thorac Soc* 2022;19:1090-2.

DOI: 10.1056/NEJMp2208613

Copyright © 2022 Massachusetts Medical Society.

---

## Double Take Video

### Sickle Cell Disease and Gene Therapy – Patient and Physician Perspectives



In this short documentary video, patients and physicians partner both to highlight the experience of living with sickle cell disease and to discuss the pathophysiology of the disease and new treatment strategies, including gene therapy.

Patients share their own stories of interactions with the health care system and explore the challenging topics of racial disparity and health equity. Physicians express a cautious optimism as they review the risks and benefits of gene therapy.

---